General Laboratory, BML, Inc.   Report issue

For profit Phase 3
Founded: Kawagoe Japan (2005)

Organization Overview

First Clinical Trial
2019
NCT03809650
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

General Laboratory, BML, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

macitentan (opsumit) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hypertension (Phase 3)

Hypertension, Pulmonary (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1